$0.00
$3.62
bear $0.00
base $1.65
bull $3.62
margin of safety $0.74
market price* $2.82
BridgeBio Oncology Therapeutics is a clinical-stage cancer drug developer spun out of BridgeBio Pharma and taken public in August 2025 through a merger with the blank-check company Helix Acquisition Corp II, together with a $260.9 million private placement. It has three drugs in early (Phase 1) human trials, all aimed at the RAS pathway: BBO-8520, which blocks the KRAS G12C mutation in both its ON and OFF states and is being tested alone and with pembrolizumab in lung cancer (ONKORAS-101; the company reported a 60% confirmed response rate in early dose-escalation patients and the FDA granted Fast Track designation); BBO-10203, which breaks the link between RAS and PI3K-alpha and is being tested in breast and colorectal cancer (BREAKER-101); and BBO-11818, a pan-KRAS inhibitor for G12D and G12V tumors (KONQUER-101). The company has no approved products, no product revenue and no partnership or licensing income. What the business earns today: nothing, and it spends heavily. Measured as cash from operations less the timing effect of working capital, less stock-based pay and less equipment spending, the business consumed about $75 million in 2024 and $127 million in 2025, and the pace is rising: the first half of 2026 used $80 million of operating cash and the second-quarter net loss of $56.5 million was the largest yet. We treat stock-based pay as a real cost. The 2025 figure includes a one-time $7.8 million non-cash charge for shares issued to BridgeBio Pharma, which is added back like any other non-cash charge. There is no historical level of positive earnings to anchor on, so the valuation rests on the balance sheet and on how much of it the trials will consume. Balance sheet: at June 30, 2026 the company held $344.1 million of cash and marketable securities against $53.6 million of total liabilities, almost all of them accrued research costs, payables and leases. It has no borrowings, no preferred stock and no warrants, so there is no debt to subtract and the business value and the equity value are the same. The company says its cash will fund operations into early 2028. There were 80.2 million shares outstanding in August 2026; 9.0 million stock options were outstanding at the end of 2025 at average exercise prices between $4.24 and $9.90, above every value below, so they are not counted as dilution. Why the drug programs are valued at zero in every case: none of the three drugs has a signed partner, a licensing contract, a late-stage trial or an approval path that can be pointed to today. Early response rates and a Fast Track designation show the science is working so far, but they do not secure any future revenue, and most Phase 1 cancer drugs never reach the market. Until a contract or late-stage result exists, we credit no future sales, royalties or milestones. Bear case ($0.00 per share): the company spends its cash on the trials into early 2028, as it has said it will, and the programs do not produce a partner or a product. With the cash gone and nothing sellable left, existing shareholders are left with essentially nothing, and any further funding would have to come from new investors on their terms. The business is worth about zero, owes nothing in borrowings, and the equity is worth about zero. Base case ($1.65 per share): the three trials already under way continue for roughly another year at the current spending pace of about $200 million a year (the second-quarter 2026 cash loss annualized), which takes the programs through their disclosed data readouts. What is left, about $140 million of cash, is worth $1.75 per share, or $1.65 discounted one year at 6%. The drugs themselves are credited nothing. The business is worth about $132 million, owes no borrowings, and the equity is worth the same. Bull case ($3.62 per share): the research spending turns out to create at least as much value as it costs, so the $344.1 million of cash and securities, less the $53.6 million the company already owes to suppliers and employees, is fully preserved as value for shareholders, about $290.5 million or $3.62 per share. We do not go above this, because anything more would require a partnership deal or late-stage trial result that does not yet exist. What would change this view: a signed licensing or co-development deal for BBO-8520, BBO-10203 or BBO-11818 with upfront and milestone payments would be real, contracted value and would raise every case. Negative safety or efficacy data, or a faster-than-expected spending increase, would push the base case toward the bear case. A new share sale below these values would dilute them. Figures come from the 2025 annual report and the June 2026 quarterly financial data; the quarterly report text itself was not available for review, so the cash runway statement relies on the annual report.